MedTrace Logo

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

NCT07385703 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 752

Last updated 2026-06-25

No results posted yet for this study

Summary

This study primarily evaluates the efficacy and safety of the LM-302 plus tislelizumab regimen versus tislelizumab plus chemotherapy in the treatment of previously untreated locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma patients with CLDN18.2 positivity.

Conditions

  • Adenocarcinoma

Interventions

DRUG

LM-302 Injection

The LM-302 injection is an ADC drug targeting CLDN18.2.

DRUG

Tislelizumab

Tislelizumab is a humanized monoclonal antibody targeting programmed cell death receptor-1 (PD-1).

DRUG

Oxaliplatin Injection

Oxaliplatin injection is a platinum-based antitumor drug.

DRUG

Capecitabine Tablets

Capecitabine tablets belong to the fluorouracil-class prodrugs.

Sponsors & Collaborators

  • Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-15
Primary Completion
2028-10-31
Completion
2030-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07385703 on ClinicalTrials.gov